A compound represented by a formula [1D] as shown below (wherein R.sup.1A, R.sup.1B, R.sup.2A, R.sup.2B, R.sup.3A and R.sup.3B represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside. ##STR00001##

A compound represented by a formula [1D] as shown below (wherein R.sup.1A, R.sup.1B, R.sup.2A, R.sup.2B, R.sup.3A and R.sup.3B represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside. ##STR00001##

A photosensitive reducible silver ion-containing composition can be used to provide electrically-conductive silver metal in thin films or patterns. This composition comprises: a) a non-hydroxylic-solvent soluble silver complex represented by the following formula (I):

(Ag.sup.+).sub.a(L).sub.b(P).sub.c(I)

wherein L represents an -oxy carboxylate; P represents an oxime compound; a is 1 or 2; b is 1 or 2; and c is 1, 2, 3, or 4, provided that when a is 1, b is 1, and when a is 2, b is 2; b) a photosensitizer that can either reduce the reducible silver ion or oxidize the -oxy carboxylate; and c) a solvent medium comprising at least one non-hydroxylic solvent. Electrically-conductive silver can be provided by photochemical conversion of the reducible silver ions in the complex.

A photosensitive reducible silver ion-containing composition can be used to provide electrically-conductive silver metal in thin films or patterns. This composition comprises: a) a non-hydroxylic-solvent soluble silver complex represented by the following formula (I):

(Ag.sup.+).sub.a(L).sub.b(P).sub.c(I)

wherein L represents an -oxy carboxylate; P represents an oxime compound; a is 1 or 2; b is 1 or 2; and c is 1, 2, 3, or 4, provided that when a is 1, b is 1, and when a is 2, b is 2; b) a photosensitizer that can either reduce the reducible silver ion or oxidize the -oxy carboxylate; and c) a solvent medium comprising at least one non-hydroxylic solvent. Electrically-conductive silver can be provided by photochemical conversion of the reducible silver ions in the complex.

The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists. ##STR00001##

The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists. ##STR00001##

A method for synthesizing a ketoxime is provided. In a system of an aqueous carbonate solution, a reaction is performed on a ketone, ammonia and hydrogen peroxide by using a titanium-silicon molecular sieve as a catalyst to obtain the ketoxime. Moreover, a reaction progress is judged and an optimal reaction ratio is determined by a real-time monitoring of a pH value in a reaction system during the reaction. In the present invention, by monitoring the pH value in the reaction system, the progress of the reaction is judged, thereby determining the optimal reaction ratio. The pH of the system is further adjusted by an aqueous carbonate solution to increase the reaction velocity and conversion rate of the ammonia.

A method for synthesizing a ketoxime is provided. In a system of an aqueous carbonate solution, a reaction is performed on a ketone, ammonia and hydrogen peroxide by using a titanium-silicon molecular sieve as a catalyst to obtain the ketoxime. Moreover, a reaction progress is judged and an optimal reaction ratio is determined by a real-time monitoring of a pH value in a reaction system during the reaction. In the present invention, by monitoring the pH value in the reaction system, the progress of the reaction is judged, thereby determining the optimal reaction ratio. The pH of the system is further adjusted by an aqueous carbonate solution to increase the reaction velocity and conversion rate of the ammonia.

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure

##STR00001##

wherein: R.sub.1 and R.sub.2 are each independently for each occurrence optionally substituted C.sub.10-C.sub.30 alkyl, optionally substituted C.sub.10-C.sub.30 alkenyl, optionally substituted C.sub.10-C.sub.30 alkynyl, optionally substituted C.sub.10-C.sub.30 acyl, or -linker-ligand; R.sub.3 is H, optionally substituted C.sub.1-C.sub.10 alkyl, optionally substituted C.sub.2-C.sub.10 alkenyl, optionally substituted C.sub.2-C.sub.10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, -aminoalkyls, -(substituted)aminoalkyls, -phosphoalkyls, -thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure

##STR00001##

wherein: R.sub.1 and R.sub.2 are each independently for each occurrence optionally substituted C.sub.10-C.sub.30 alkyl, optionally substituted C.sub.10-C.sub.30 alkenyl, optionally substituted C.sub.10-C.sub.30 alkynyl, optionally substituted C.sub.10-C.sub.30 acyl, or -linker-ligand; R.sub.3 is H, optionally substituted C.sub.1-C.sub.10 alkyl, optionally substituted C.sub.2-C.sub.10 alkenyl, optionally substituted C.sub.2-C.sub.10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, -aminoalkyls, -(substituted)aminoalkyls, -phosphoalkyls, -thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).